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Abstract
During infection with human immunodeficiency virus (HIV), immune pressure from cytotoxic T-lymphocytes (CTLs) selects
for viral mutants that confer escape from CTL recognition. These escape variants can be transmitted between individuals
where, depending upon their cost to viral fitness and the CTL responses made by the recipient, they may revert. The rates of
within-host evolution and their concordant impact upon the rate of spread of escape mutants at the population level are
uncertain. Here we present a mathematical model of within-host evolution of escape mutants, transmission of these
variants between hosts and subsequent reversion in new hosts. The model is an extension of the well-known SI model of
disease transmission and includes three further parameters that describe host immunogenetic heterogeneity and rates of
within host viral evolution. We use the model to explain why some escape mutants appear to have stable prevalence whilst
others are spreading through the population. Further, we use it to compare diverse datasets on CTL escape, highlighting
where different sources agree or disagree on within-host evolutionary rates. The several dozen CTL epitopes we survey from
HIV-1 gag, RT and nef reveal a relatively sedate rate of evolution with average rates of escape measured in years and
reversion in decades. For many epitopes in HIV, occasional rapid within-host evolution is not reflected in fast evolution at
the population level.
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Introduction
During the course of a single infection HIV evolves to escape
from the selection pressures imposed by its host’s immune
response. Such changes have been recorded under selection from
all three arms of the specific immune response, but escape from
CD8+ cytotoxic T lymphocytes is particularly well documented
[1,2,3,4,5]. HIV variants that cannot be recognised by current
host CTLs are termed ‘‘CTL escape mutants’’. Such mutants have
been shown to transmit from one host to another [6,7], raising
their status from potential causes of pathogenesis within
individuals [8,9,10,11] to potential drivers of evolutionary change
across the global HIV pandemic [12,13,14,15,16].
Different hosts make immune responses to different parts of
HIV (known as epitopes) and for CTL responses the epitopes that
can be recognised are determined by the host’s class 1 human
leukocyte antigen (HLA) type. CTL escape mutants can revert to
the wild-type when they are no longer under selection pressure
from host immune responses [17,18]. Global change in HIV’s
CTL antigens is therefore driven by three parallel processes: the
selection of escape mutants in hosts whose immune response can
recognise a given epitope (HLA matched hosts), transmission to
new hosts, and reversion of escape mutants in hosts unable to
recognise the epitope in question (HLA mismatched hosts).
A large literature describes the evolution of HIV CTL escape
mutants within individual hosts. Many of those papers are case
reports of the timing and speed of outgrowth of escape mutations
within an individual and in most cases the events described occur
during the first year of infection [3,5,19,20]. The accumulated
wisdom from this literature is that the evolution of HIV is always
very rapid, that this is strong evidence that CTL immune
responses are highly effective and that this viral evolution would
pose a severe threat to the durability of any HIV vaccine. This is a
received wisdom that is worth serious review as it has profound
influence on how we think about the interaction between HIV and
its human hosts.
A better understanding of the global tempo of antigenic change
in HIV can be achieved by addressing a series of specific questions.
On average, how fast do HIV escape mutations arise in HLA
matched individuals? How fast do reversions occur in HLA
mismatched people? HIV is a relatively recently emerged infection
of humans; so is it still adapting to its new hosts, and if so, how
fast? What is the relationship between the tempo of adaptation
within individuals and the rate of genetic change across the entire
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pandemic? If HIV is still adapting, what patterns can we expect to
unfold across the population of infected people? How will those
patterns be different in people of different HLA types and in
populations with different HLA frequencies?
Some of these questions have been elegantly addressed in large
observational studies which describe the patterns of events that
have unfolded in recent decades [12]. In order to understand the
processes that underlie those patterns, and to predict what future
patterns we might expect we need mathematical models of within-
host evolution and between-host transmission that are firmly
rooted in the relevant data. There is a substantial literature on
mathematical models of the evolution of HIV. Much of it has
focussed on the within-host dynamics of HIV variants, either
selected by immune responses [4,21,22] or by antiviral drugs
[23,24,25]. Another literature focuses on models of the spread of
drug resistance [26,27]. By comparison, limited attention has been
paid to the two-level problem of the evolution of CTL escape
mutants within hosts and the spread of those mutants between
hosts [28].
Results
In order to address this gap we have developed a mathematical
model that simultaneously captures events while viruses evolve
within individuals and tracks the spread of variants as viruses are
transmitted between individuals. Between-host transmission is
modelled using a standard mathematical description of the
frequency-dependent transmission of an infectious disease from
which there is no recovery – the so-called SI model. However, the
model we present allows host-heterogeneity with respect to a single
HLA type so that some hosts have the potential to make a CTL
response to a given viral epitope, whereas other hosts do not. Viral
evolution is captured by allowing viral heterogeneity with respect
to the presence – or not – of escape mutations in a single epitope
restricted by the host HLA under consideration. Thus there are
four types of infected hosts: HLA matched hosts infected with
wild-type or escape mutant virus, and HLA mismatched hosts
infected with wild-type or escape mutant virus. Thus there are no
mixed infections, or more precisely each host can only be
infectious with one type of virus. Only HLA matched hosts
infected with wild-type virus can mount effective CTL responses to
the viral epitope under consideration. They drive the evolution of
CTL escape mutants and can therefore switch to become HLA
matched hosts infected with escape mutant virus. HLA mis-
matched hosts are unable to mount CTL responses to the given
epitope whatever mutations it bears and they can therefore allow
their infecting virus to revert from escape mutant to wild-type. In
this model such viral reversion is represented by HLA mismatched
hosts switching from being infected with the escape mutant virus to
being infected with the wild-type virus. Every infected host is
infectious with the viral type they carry, so that the two viral types
are transmitted between individuals at rates driven by the
proportion of the total population infected with each. A diagram
of the model is presented in Figure 1A and the parameters,
variables and equations defining the model are provided in the
Methods section. Figure 1B illustrates the three phases of an
epidemic predicted by our model (and therefore also by the
standard SI model): initial exponential growth, saturation, and
then stabilisation at an endemic equilibrium. The model structure
and parameter values we have used are appropriate for modelling
HIV within a single, closed high-risk group. Since the majority of
the data that we analyse will be from individuals belonging to high
risk groups this is an appropriate approximation.
This model has similarities to mathematical models of the
spread of drug resistance [29]. HLA matched hosts being
equivalent to hosts taking antiviral drugs and CTL escape mutant
virus equivalent to drug resistant virus. However, in this model,
hosts never change their type so the model is structurally different
from drug resistance models and new analyses are needed.. Unlike
the gene-for-gene models of the world of plant pathology [30] this
model is also not designed to consider host and pathogen co-
evolution. Here, birth rates are independent of current host
densities (see Figure 1A) so a different model structure that
combined pathogen evolution as explored here and host changes
as explored, for example, in Cromer et al. (2010) [31], would be
needed to explore co-evolution of HIV and humans.
Figure 1C summarises the time-course of population prevalence
for an escape mutant that arises at the start of an epidemic. Three
features are noteworthy. First, there are qualitatively different
patterns for mutants with different rates of escape and reversion.
For escape mutants that never revert or revert very rarely (e.g.
once in 50 person-years of observation) we would currently expect
the prevalence of escape in the population to be increasing. On the
other hand, if reversion is more rapid, we would expect the
population prevalence of escape to have already stabilised at a
plateau before entering a second transient phase to reach its
eventual equilibrium value. The early plateau occurs because at
this stage, although the number of HLA matched and HLA
mismatched hosts with each virus type are growing exponentially,
they are growing at equal rates. Second, the predicted prevalence
of escape is both qualitatively and quantitatively very sensitive to
the reversion rate if reversion is slow. Notice the dramatic
difference in the long-term between a zero rate of reversion and a
very slow rate of reversion (Figure 1C crosses versus triangles). If
reversion never happens then the escape mutation will eventually
fix – although this could take centuries. However, even a rate of
reversion that could only be observed in a large cohort study (once
in 50 person-years of observation) would prevent fixation of the
escape mutant in the population, with an initial rise in prevalence
followed by a fall and eventual stabilisation. Thirdly, faster rates of
escape and slower rates of reversion lead to higher population
prevalence of escape. However the underlying epidemic dynamics
of in the community under study and the proportion of HLA
matched hosts in the population [12] will also affect the prevalence
of escape.
In each of Figures 1D and 1E escape prevalence is tracked in
the two different host populations: HLA matched (black lines) and
HLA mismatched (red lines). As one would expect, escape
Author Summary
HIV evolves so quickly that it can be seen to adapt within
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particularly well-described. Escape variants transmit to
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evolution of escape mutants, transmission of those
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rates of escape measured in years and reversion in
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literature of early and rapid within-host evolution of HIV,
for many epitopes this is not reflected in fast evolution at
the population level.
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Figure 1. A mathematical model of within-host evolution and between-host transmission of escape mutants at a single CTL
epitope. A) The mathematical model in schematic form, where WT and EM denote the wild-type strain and escape mutant strain, respectively. B)
Changes in numbers of susceptible (
P
h~1,2
Xh(t)) and infected (
P
h~1,2
P
v~1,2
Yhv (t)) hosts over time showing the three phases of the epidemic: exponential
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prevalence is always higher in HLA matched than HLA
mismatched hosts and increases with faster escape rates
(Figure 1D) or slower reversion rates (Figure 1E). Furthermore,
when reversion takes an average of approximately 10 years or less,
the prevalence in both host types achieves a temporary plateau
during the exponential phase of an epidemic. Analytic expressions
for the temporary plateau, the long-term equilibria and the time-
course of escape prevalence during the initial years of the epidemic
are presented in the Text S1.
In Figure 1 we plot results as prevalence of infection with escape
mutant viruses in infected hosts of different types. Incidence is also
of interest, but in this model incidence is driven by prevalence so
the proportion of new infections that carry escape mutations will
always be the same as the proportion of prevalent mutations that
carry escape mutations.
The model’s behaviour can be compared with CTL escape data
from the current HIV pandemic. Such data are available from
diverse studies, summarised in Figure 2. Throughout this study we
define escape as any mutation at a site at which an escape mutation
has been described (and phenotypically demonstrated in vitro).
Escape data are available at two levels of organisation:
comparisons across individuals (Figures 2A and 2B) and changes
within individuals (Figures 2C–F). Figure 2A (dataset 1) tracks
changes through time in the proportion of hosts with escape
mutations in six different epitopes. These data were downloaded
from the Los Alamos HIV sequence database (www.hiv.lanl.gov)
using a search for dated B-clade sequences and eliminating
duplicate samples from the same individual. Although this
database is not strictly an epidemiological survey, it is the largest
source of temporal population level data. The six epitopes are a
subset of 31 epitopes in gag, reverse transcriptase (RT), and nef for
which at least one escape mutation has been described in the
literature. Details and references for these mutations are provided
in Table S1 and Text S2. None lie at defined drug resistant sites
according to Stanford HIV Drug Resistance Database (http://
hivdb.stanford.edu/). As predicted in Figure 1C, different epitopes
show different behaviour; in some the prevalence of escape has
remained stable over several decades (filled markers), whereas in
others the prevalence of escape has been increasing (unfilled
markers). In Figure 2B (dataset 2), for 26 epitopes with described
escape mutants in gag, RT and nef the prevalence of escape in
HLA matched and HLA mismatched hosts amongst 84 individuals
with chronic infection is presented. These patients, the majority
(76%) of whom have HIV-1 subtype B, have been described in
detail elsewhere [32,33,34]. Data for the remaining 5 (out of 31)
epitopes were not available (Table S2). The data presented in
Figure 2B should be compared to the model predictions in
Figures 1D and 1E. As expected, escape is more prevalent in HLA
matched than mismatched individuals (for given parameters black
lines are above red lines in 1D and 1E, while points in 2B lie below
the line y = x), but otherwise, across different epitopes the
prevalence of escape is very variable (at a fixed time point in 1D
or 1E prevalence of escape for different epitopes can vary widely,
in 2B epitopes are liberally scattered across the bottom right half).
The other type of data on the dynamics of escape and reversion
tracks events as they occur within infected individuals. One source
of such data (dataset 3) is case reports of single HIV-1 infections,
recording the time after infection when escape or reversion
occurred. Around 55 such escape events in 28 different epitopes
across the full genome are described in the literature (Figure 2C,
Table S3 and Text S2), but only 3 such reversions (Figure 2D,
Table S4 and Text S2). For most epitopes there are only one or
two records of time to escape and those are within the first few
years of infection. It is common for the data summarised in 2C to
be taken as indicating that the rate of escape is generally rapid.
Collating individual records of time to escape cannot yield an
estimate of the rate of escape as these studies typically ignore the
existence of individuals in whom nothing interesting happens. To
estimate escape and reversion rates longitudinal cohort studies are
typically used. Early results from one such cohort study of 189,
acute seroconverters are summarised in Figures 2E and 2F (dataset
4). These individuals are mostly B-clade (87%) and have been
described previously [35]. They were first sampled a median of 6
weeks following their estimated date of seroconversion and were
followed for a mean further 1.9 years (range: 0.5–5 years). It is
clear from Figure 2E that the published literature on time to
escape (Figure 2C) is heavily biased towards early escape events
and that when a cohort is followed, amongst all hosts who are
HLA matched for any given epitope and infected with wild-type at
first sample (N in Figure 2E), many show no escape in the early
years of infection. The absence of escape events amongst many
hosts implies that escape is slow. For example, the average time to
escape in epitope KRWIILGLNK (HLA B27-restricted, HXB2
p24 gag 131–140) is 11.1 years because escape events occurred in
only 3 out of the 17 HLA B27 hosts who had the wild-type at the
first sample. Reversion events are similarly sparse in comparison to
the numbers of HLA mismatched hosts who had each escape
mutant at first sample (Figure 2F). Reversion rates are therefore
also slow.
We do not have to wait several decades for longitudinal cohort
studies to play out. Our model can be used to infer rates of escape
and reversion from HLA-typed escape prevalence data such as
that shown in Figure 2B. To make these inferences we need
estimates of the basic reproduction number, R0, (defined as the
expected number of secondary cases arising from a typical infected
individual when all other members of the community are
susceptible), the average life expectancy of infected hosts, the
duration of the HIV epidemic in the sample population and the
proportion of the population who are HLA matched for each
epitope. Since the data in 2B are from Switzerland, we assume that
HLA prevalences are equal to those found in Caucasians [36] and
that the epidemic duration at the time of sampling (year 2000) is
27 years [37]. Further, we use a basic reproductive number of 3
[38] and an average life expectancy of infected hosts of 10 years
[39]. With these parameters fixed, we use the model to fit only two
parameters – the escape and reversion rates – from two
observations – the proportions of HLA matched and HLA
mismatched hosts with escape. For fixed model parameters, escape
prevalences in both host types strictly increase with faster escape
rates and slower reversion rates, thus any unique pair of rates
correspond to a unique pair of escape prevalences. The model can
therefore be fitted very simply using ‘least-squares’ to find the
growth, saturation and equilibrium. C) Changes through time in the proportion of infected hosts with escape at a single CTL epitope for different
escape and reversion rates. D and E) Changes through time in the proportion of HLA matched (black lines) and HLA mismatched (red lines) hosts
infected with escape at a single CTL epitope for different escape and reversion rates. Different escape rates are compared in D) and different reversion
rates are compared in E). The following initial conditions and parameters were used for these plots: X1(0) = 104, X0(0) = 9|104 , Y 10 (0)= 0.1, Y
0
0 (0)=0.9,
Y 11 (0)~Y
0
1 (0)= 0, p=0.1, m= 1/50 years
21, m+a= 1/10 years21, bc = 0.3 and B=105m years21. These parameters yield a basic reproduction number of
3, since for this model R0 =bc/(m+a).
doi:10.1371/journal.ppat.1001196.g001
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Figure 2. CTL escape and reversion data from the current HIV pandemic. A) Dataset 1: the evolution of previously described escape mutants
in six CTL epitopes. Data from dated B-clade sequences provided in the Los Alamos database. The filled shapes show three epitopes for which the
proportion of hosts with escape has remained relatively invariant over the past 20 years. The unfilled shapes show three epitopes for which the
proportion of hosts with escape has increased over the last 20 years. B) Dataset 2: cross sectional data describing the proportion of HLA matched and
Modelling the Spread of HIV Immune Escape Mutants
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unique pair of escape and reversion rates that minimise the
difference between the observed and expected escape prevalences.
Figure 3 shows the inferred mean time to escape (3A; x-axis
values) and mean time to reversion (3B; x-axis values) for each
epitope estimated from the cross-sectional escape prevalence data
in Figure 2B (dataset 2). Ninety five percent confidence intervals
surrounding these estimates are shown in Figure S1. Confidence
differs between epitopes because of differences in the underlying
evolutionary rates and in the number of hosts who are HLA
matched and mismatched for each HLA type. Nevertheless, even
with our relatively small total sample size (84 individuals), for most
epitopes the confidence is sufficient to distinguish between rates
measured in months, years or decades. These confidence intervals
account for sampling errors, but assume that the structure and
parameters of the model are a perfect representation of the system.
Figure S2 shows how our assumed global parameters (the basic
reproductive number, life expectancy of infected hosts, epidemic
duration and HLA prevalences) affect our inferences. These
analyses reveal that while the magnitude of our escape and
reversion rates change with each of these parameters, their rank
orders remain largely preserved.
To test our model predictions, escape and reversion rates for the
same epitopes were determined from the independent longitudinal
cohort data (dataset 4) presented in Figures 2E and 2F. Although
this cohort is relatively new it is still possible to estimate mean
escape and reversion rates by taking account of all individuals,
those who demonstrate escape or reversion and those who do not.
Since very many individuals have not yet demonstrated escape or
reversion (few dots in Figures 2E and 2F compares to N for each
epitope) many of our estimates of mean escape and reversion rates
are long compared with the duration of the cohort study. Thus the
fact that the y–axis of Figure 3A runs to .50 years whilst that of
Figure 2E only extends to 5 years is a reflection of the large
number of person-years of observation in which no escape occurs
summarised in Figure 2E. Figure 3A reveals that the inferred
escape rates estimated from the two population studies are not just
highly correlated (Pearson’s correlation coefficient (PCC) = 0.83,
2-tailed p-value,0.001, N= 24) but are also approximately equal
in magnitude (2-tailed paired t-test, H0: difference = 0, t-
value =20.17). Figure 3B also shows a positive correlation
between the observed and inferred reversion rates. For this
comparison significance just misses the standard 0.05 p-value
boundary (Kendall Tau correlation coefficient (KTCC)= 0.32, p-
value = 0.06, N= 25). It is noteworthy, however, that the
correlation is highly significant (KTCC=0.68, p-value,0.001,
N= 21) if we exclude the four epitopes for which we have least
confidence in our inferred rates (Figure S1). These reversion rates
are also approximately equal in magnitude (2-tailed paired t-test t-
value = 0.87, N= 21).
We can take the inferred rates of escape and reversion and use
the model to calculate a predicted change over 20 years (1985–
2005) in the population escape prevalence of each epitope. When
we compare that predicted change with the observed change in
sequences deposited in the Los Alamos database (Figures 3A,
dataset 1, Figures 2A and S3) we find that these values are strongly
correlated (Figure 3C; PCC=0.78, 2-tailed p-value,0.001,
N= 26) and not significantly different from each other (2-tailed
paired t-test t-value =21.58). Thus, the model is able to explain
why some escape mutants appear to have stable prevalence, whilst
others are spreading through the population. To calculate these
predicted changes, the initial conditions of the model are defined
so that the proportion of hosts with escape is equal to the
proportion observed in dataset 1 at the earliest sample time. Since
individuals in dataset 1 are not HLA-typed, the initial conditions
are also defined so that the ratio of HLA matched to HLA
mismatched hosts with escape is equal to the ratio observed in the
cross sectional data (Figure 2B).
Our interpretation of the data in Figure 2 is that datasets 1, 2
and 4 yield consistent estimates across many epitopes. Both escape
and reversion rates are slow. It is only the data from small studies
of one or two people in dataset 3 which imply that escape rates are
usually rapid. The studies summarised in 2C are mostly individual
case reports and do not give a reliable picture of time to escape as
there is strong publication bias in favour of papers describing
escape events and against case studies of individuals in whom
nothing happened. Escape rates estimated from population data,
whether longitudinal (Figure 2E and y axis Figure 3A) or cross-
sectional (Figure 2B and x axis Figure 3A) reveal that, on average,
escape is typically much slower than the individual case reports
suggest. As shown in Figure 2C, escape has previously been
described as typically occurring within the first year of infection
(median time to escape= 0.44 years; interquartile range
(IQR) = 0.25–1.3 years); however, our population-based estimates
imply that only 3 out of the 26 epitopes surveyed here have an
inferred mean time to escape of less than a year. Across all 26
epitopes the median inferred time to escape is 8.0 years and the
IQR is 1.8–34.0 years. It must be emphasized that these estimates
refer to escape in any HLA matched hosts. Hosts who are HLA
matched for a given epitope have the potential to make an
immune response to that epitope, but do not necessarily do so.
Indeed, one study indicates that, on average, responses to any
given epitope are made by only a third of HLA matched hosts
[33]. Escape rates in the presence of an immune response could
therefore be three times faster than the rates estimated in this study
and this may go part way towards explaining why the escape rates
derived from the case-reports – where CTL responses are
measurable – are faster than those estimated here. However it is
not enough to explain the close-to 20-fold difference uncovered
HLA mismatched hosts with described escape mutants in gag, RT and nef. Each dot represents the data for a single CTL epitope (N= 26). Data from 84
chronically infected hosts from Switzerland. C) Dataset 3: escape data from individual case reports described in the literature. Each marker represents
the results from one HLA matched host infected with the wild-type epitope at the first sample time. In cases where escape occurred the time
between infection and escape is represented by a circle. In cases where escape did not occur the time between infection and the last sample is
represented by a triangle. The inferred average time to escape is represented by a horizontal bar. These averages account for data, where available
(triangles), from hosts in whom escape mutants do not appear (see Table S3 for details). D) Dataset 3: reversion data from individual case reports
described in the literature. Each marker represents the results from one HLA mismatched host infected with a described escape mutant at a particular
epitope at the first sample time. The markers are analogous to those described for C). E) Dataset 4: escape data from a longitudinal cohort of 189
acute seroconverters. Estimates are provided for 27 epitopes with previously described escape mutations in gag, RT and nef. These are largely the
same epitopes shown in B), though there is some lack of overlap due to the absence of certain data from one or other dataset. N is the number of
HLA matched hosts infected with the wild-type epitope at the first sample. In cases where escape occurred, the time between infection and escape is
represented by a dot. F) Dataset 4: reversion data from the same longitudinal cohort of individuals. For each epitope N is the number of HLA
mismatched hosts infected with an escape mutant at the first sample. In cases where reversion occurred, the time between infection and reversion is
represented by a dot.
doi:10.1371/journal.ppat.1001196.g002
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here. Our assumed global parameters also do not explain this
difference. Plausible alternative parameter choices do change the
magnitude of our inferred rates, but not to this extent (Figure S2).
Our inferred reversion rates are even slower than our inferred
escape rates: there is no reversion in 56% of epitopes and at the
lower quartile the average time to reversion is 6.5 years. As shown
in Figure 1C, however, even a slow but non-zero reversion rate
can prevent fixation of an escape mutant at the population level.
The longitudinal cohort also reveals that reversion is slow (time to
reversion: median = 36.4 years, IQR=13.0 years-no reversion).
For neither dataset do the escape rates correlate with the reversion
rates.
It is surprising to find that the rate of escape from CTL
selection is more than an order of magnitude slower than
suggested in a substantial literature describing events in carefully
followed individuals. It is reassuring that the result arises very
consistently from two different analyses of two independent
datasets. Estimating escape and reversion rates from longitudinal
cohort data is a straightforward and well-established process (see
Figure 3 legend). Our estimates from the cross-sectional data
require inference based on the new model we have presented
here. That model is deliberately kept simple to allow a
transparent explanation of what assumptions we have made
and to minimise the number of other parameters we must fix
when using the model to estimate escape and reversion rates. But
with such a simple model the question must arise, is the result
simply an artefact of leaving out too much of the relevant
biology? In what follows we explore a series of six complicating
factors that might change the rates of escape and reversion
inferred from the cross sectional data. In each case we find that
our results are robust to the inclusion of extra biological
complexities in our model structure or alternative definitions of
escape mutants. The details of data interpretation and model
development are, for the sake of brevity, presented in the
supplementary materials. Here we summarise the results.
Might our definition of escape have excluded many genuine
escape mutations? We confined our analysis to mutations at sites
that have been demonstrated in vitro to confer escape. This curbs
Figure 3. Observed and inferred escape rates, reversion rates
and changes in escape prevalence. A) A comparison of the mean
times to escape inferred from dataset 2, the cross-sectional data (x-axis)
and observed in dataset 4 (Figure 2E), the longitudinal cohort study (y-
axis). B) A comparison of the mean times to reversion inferred from
dataset 2 and observed in dataset 4 (Figure 2F). For A) and B) estimates
are provided for epitopes in gag, RT and nef for which escape mutants
have been described and for which data are available from both
studies. The inferred rates (x-axes) are calculated from dataset 2 using
the mathematical model. For A) the observed times to escape (y–axis)
are calculated from dataset 4 by considering all HLA-matched hosts
who have the wild-type epitope at the first sample. We then sum over
all person-years of observation for which an escape mutant is absent
and divide by the number of hosts in whom escape mutants emerge.
For B) reversion rates from dataset 4 are estimated using an analogous
method from all HLA-mismatched hosts who have an escape mutant at
the first sample. Note that the epitopes in these graphs are the same as
those presented in Figure 2B, except that, epitope FLK is absent from A)
and epitope ETF is absent from both A) and B) because the relevant
estimates were not available from dataset 4. The data are presented on
a linear scale from 0–10 years and on a log scale beyond 10 years. In B)
the crosses represent the four epitopes for which we have the least
confidence in our inferred reversion rates (see Figure S1). The remaining
epitopes are shown as circles. C) A correlation between observed and
predicted changes in the escape prevalence of described escape
mutants in gag, RT and nef in the population between approximately
1995 and 2005. These are the same 26 epitopes as shown in dataset 2.
The observed changes are from sequence data downloaded from the
Los Alamos Database (dataset 1, Figures 2A and S3). The predicted
changes over the same period are estimated using the mathematical
model parameterised by the escape and reversion rates inferred from
dataset 2 (x-axes 2A and 2B).
doi:10.1371/journal.ppat.1001196.g003
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both the epitopes we look at and the sites within those epitopes
that we consider. To check for bias arising from only looking at
sites with defined escape we replot Figure 2B redefining escape as
any mutation within the epitope (Text S3, factor 1). We find that,
for all but 2 of the 26 epitopes, any increase in the inferred escape
rate would be marginal or none. To check for bias arising from our
choice of epitopes we replot Figure 2B to include all known
epitopes in gag, RT and nef, regardless of whether or not an
escape mutant has ever been described in that epitope. The figure
includes the 26 epitopes we have already investigated and 48 other
epitopes for which no escape mutation has ever been described. All
of the 48 new epitopes have roughly equal prevalence of mutated
epitopes in HLA matched and mismatched hosts. Thus, if
anything, our choice of epitopes has tended to focus attention
on those epitopes where escape and reversion are faster.
It is an inbuilt assumption of our model that escape mutants do
not revert in HLA matched hosts. In principal such reversion
could lead to lower prevalence of escape in HLA matched hosts
and consequent underestimation of escape rates. The longitudinal
cohort study (dataset 4) allows an estimate of the rate at which
escape mutants revert in HLA matched hosts. The estimate is that
this occurs, on average, once every 25 person-years of observation.
Using this estimate and a modified version of our model in which
escape mutants can revert in HLA matched hosts we can re-
estimate escape and reversion rates from the data in Figure 2B and
the new model (Text S3, factor 2). We find that the new estimates
of escape rates are marginally (less than 10%) faster and that
reversion rates are barely affected at all. If the rate of reversion in
HLA matched hosts is as small as that observed in our longitudinal
study then such reversion would not substantially affect inferred
rates of escape and reversion.
Another possibility is that some escape mutations only appear
transiently, to be replaced by other mutations in the same epitope.
We develop a model of such a process in Text S3 (factor 3). We
find that transitions between different escape mutants at the same
epitope would not affect the evolution of escape mutants at the
population level. This is because if an individual with one
particular escape mutant selects another escape mutant in place of
the first, the total number of hosts with escape remains the same.
As a result, transitions between escape mutants would not affect
the rates of escape and reversion inferred from the cross-sectional
data using the original model.
We have assumed that the rates of escape and reversion are
homogenous across the duration of infection. In principal, if
escape is faster earlier on during infection the prevalence of escape
mutants in the population would be lower than would be predicted
under the assumption that escape is as fast late on as it is early on
during infection. This would lead us to underestimate the rate of
escape during the early stage of infection. Instead, our estimate
would represent a form of average escape rate across both the
early and late stages of infection. Likewise, faster reversion in early
infection could affect the prevalence of escape mutants and thus
our inferred rates. Using a model in which escape and reversion
are both faster in the first year of infection and an estimate (based
on an upper bound from the longitudinal cohort study) that both
rates halve after the first year we re-analysed the cross-sectional
data to see how estimates change under these different assumption.
We found that both inferred escape and reversion rates are faster
under these new assumption but the halving of rates after 1 year is
not large enough to have a substantial effect upon the escape
prevalence at the population level and thus upon our inferred rates
of escape and reversion. Details of the model and of the data
supporting a halving of rates after one year are presented in Text
S3 (factor 4).
We have also assumed that people are equally infectious
throughout their infection. A study of HIV-discordant heterosex-
ual couples [40] found that transmission is 10 times more likely in
the first 2.5 months of infection compared with the chronic phase
of infection. We developed a model in which transmission is much
faster during acute infection than later (Text S3, factor 5). We
found that realistic differential transmission rates between acute
and chronic infection would have very little impact upon the
prevalence of escape mutants in the population. There are two
reasons for this. Firstly, even if, as estimated, transmission is 10
times faster during acute infection than during chronic infection,
acutely infected hosts still account for a minority of infections
because acute infection is short compared to the whole duration of
an infection. Indeed, it is estimated that only 15–20% of all
infections can be attributed to acutely infected hosts [40,41]. In
addition to this, the escape prevalence at the population level is
highly dependant upon the rates of within-host evolution and not
just upon the transmission of escape mutants between hosts. Model
simulations show that together these factors would have no
noticeable impact upon the evolution of escape mutants or upon
our inferred rates of escape or reversion.
Throughout this analysis we have treated different epitopes as
though they were independent entities. Of course that is not so and
the most intimate way in which epitopes can interact is by lying in
identical parts of the HIV genome. Many CTL epitopes do lie in
overlapping sections of the genome and we therefore developed a
model to investigate the dynamics of a mutation at a single site that
confers resistance in two overlapping epitopes restricted by two
different HLA alleles (Text S3, factor 6). We find that analysing
overlapping epitopes as though they were independent of each
other typically leads to underestimation of the reversion rate but
overestimation of the escape rate. Overlapping epitopes therefore
cannot explain why the escape rates estimated from the cross-
sectional data are so slow.
Discussion
In the introduction we posed a series of questions about the
tempo of antigenic change in HIV within individuals and at the
population level. Here we summarise our answers to those
questions.
On average, how fast do HIV escape mutations arise in HLA
matched individuals? We find that the median time to escape in
HLA matched individuals across the 26 epitopes considered here is
8 years with an interquartile range of 1.8–34.0 years.
How fast do reversions occur in HLA mismatched people? Our
inferred reversion rates are slow: there is no evidence of reversion
in 56% of epitopes and at the lower quartile, the average time to
reversion is 6.5 years.
These estimates, inferred using the model presented here from
cross sectional population data, are highly consistent with
independent estimates from an independent longitudinal cohort
study. Taken together, these estimated rates of within-host
evolution can accurately predict population level changes in the
prevalence of escape mutants over the past 20 years for these 26
epitopes. The only data inconsistent with these estimates are the
case studies which have driven the accumulated perception that
escape is rapid and common. But case studies are subject to
publication bias in favour of dramatic events and are not a reliable
source of information on average rates of evolution across the
population.
Is HIV still adapting to humans and if so how fast? We believe
that HIV is still adapting to humans, and that the tempo of
adaption will be different for different epitopes. We expect the
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prevalence of escape in some epitopes to carry on increasing far
into the future, but only slowly.
What is the relationship between the tempo of adaptation within
individuals and the rate of antigenic change across the entire
pandemic? If HIV is still adapting, what patterns can we expect to
unfold across the population of infected people? Depending on the
rates of evolution within hosts we expect three different patterns of
change in the prevalence of escape mutations. If the rate of
reversion is zero then we expect the prevalence of escape
mutations to carry on climbing, slowly, until they become fixed.
If escape rates are fast or HLA prevalence is high then the rate of
increase will be faster, but the expected qualitative pattern of slow
rise in prevalence is independent of the escape rate. This pattern is
illustrated in the curves in Figures 1C and 1D in which escape
mutants never revert. It is perhaps counter-intuitive that it is
epitopes with the very slowest reversion rates that we expect to
display the most obvious population-level increases. For epitopes
in which reversion is fast, or reversion and escape are both slow we
expect the current prevalence of escape to be close to its long term
level. Finally, if escape is fast and reversion is slow we expect the
population prevalence of escape to fall as the underlying epidemic
approaches its own long-term equilibrium. This third pattern is
illustrated in the curve in Figure 1C with mean time to escape of 1
year and mean time to reversion of 10 years. These patterns are
illustrated for particular parameter values in figure 1C and
described for all possible parameter values in the analytic results
presented in equations (S9) and (S12) of the Text S1.
How will these patterns be different in people of different HLA
types in populations with different HLA frequencies? As one
would intuitively expect, other things being equal, escape
prevalence is lower in HLA mismatched people than HLA
matched. It is also intuitively appealing that if the rate of reversion
for an epitope is faster, then the discrepancy between prevalence in
the two groups is greater. We also expect different dynamics in the
HLA matched versus mismatched populations with escape
prevalence in the two groups diverging in the years following the
peak in the underlying epidemic. Of course this pattern is not what
we expect if the reversion rate is zero in which case prevalence of
escape slowly converges to fixation in both groups.
Finally, how will these patterns be different in populations with
different HLA frequencies? The equations describing the tempo-
rary and final plateau in HLA matched, mismatched and total
populations (Text S1, equations (S7)–(S12)) illustrate the intuitively
appealing result that, other things being equal, escape prevalence
increases with the underlying prevalence of HLA that restricts the
escaping epitope.
Did our strict definition of escape bias our results towards those
epitopes that evolve more slowly within hosts? We have explored
the sensitivity of these results to different definitions of escaped
epitopes and find that, if anything, our definition leads us to focus
on epitopes that escape and revert more quickly. Nevertheless, this
analysis only considers epitopes in gag, RT and nef restricted by
HLA class I A and B alleles. HLA C-restricted epitopes [42] and
epitopes in env and the accessory/regulatory genes may behave
differently. Recent studies of the very first weeks of infection have
described very early and rapid CTL escape in env in a small
number of individuals [5,43]. If these individuals are representa-
tive of the population, this intense early escape will be reflected in
population prevalence of these env mutations. However the
analysis presented here is a worked example of how events in a
small number of individuals are not always representative of the
wider population. Finally, as noted earlier, our escape rates are
averaged across all HLA matched hosts. If only one third of HLA
matched hosts actually mount a given epitope-specific response
[33] our estimates of escape rates in hosts who mount a response would
increase three-fold. This is not enough to reconcile the 20-fold
difference between rates estimated from case-study data versus
population data.
Model assumptions are another potential source of bias. We
have presented a series of five additional models to check for the
structural sensitivity of our findings. We find that none of the five
different, more complex models we use to reinterpret the cross
sectional data substantially alter our estimates of escape and
reversion rates. These results are robust under several alternative
models and different data definitions.
However we have not exhausted the infinite range of potential
models we could use to better understand these questions. In
future work we would hope to explore a number of further
complications. Perhaps the most intriguing is to investigate the role
of epistatic interactions between epitopes [44]. Although we have
already considered overlapping epitopes, the role of more subtle,
perhaps long-range interactions is clearly of great interest. We can
also relax more of the assumptions of the simple model: that
virulence and infectiousness are the same regardless of the host-
virus pairing; that hosts can only ever transmit the type of virus
which dominates their own infection; or that populations mix
heterogeneously both socially and spatially. However, finding
enough data to keep such complex models grounded in reality may
be challenging.
This model provides a new framework with which to investigate
how within-host evolution of CTL escape mutants translates to
evolution of HIV at the population level. We have used it here to
explain why some escape mutants have stable prevalence, whereas
others continue to spread through the population. We have also
used it to estimate within-host escape and reversion rates from
population-level, cross-sectional sequence data. This is a useful
tool since cross-sectional studies are faster, cheaper and often
larger than longitudinal studies. Interpreting longitudinal studies is
made difficult because mutants present at the first sample may
have been transmitted or may have escaped prior to the first
sample. Both cross-sectional data and this model include both
means by which an individual can acquire an escape mutant and
our rate estimates therefore account for them. In broader terms,
this model allows comparisons across diverse sources of data on
CTL escape. Although the model makes several simplifying
assumptions, it reveals striking agreement across diverse and
independent datasets: for most of the epitopes surveyed here,
averaged across HLA matched individuals, escape happens slowly.
Materials and Methods
Ethics statement
This study has been approved by the Multicentre Research
Ethics Committee (MREC). All patients provided written
informed consent before participating in this study.
Variables and parameters of the model
N t= time
N h=host type (0 if HLA mismatched, 1 if HLA matched)
N v=virus type (0 if wild-type (WT), 1 if escape mutant (EM))
N B=population birth rate (years21)
N p=proportion of the population who are HLA matched
N w= rate of escape in HLA matched hosts (years21)
N y= rate of reversion in HLA mismatched hosts (years21)
N m=death rate of susceptible hosts (years21)
N a=disease-related death rate (years21)
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N b= transmission probability per partnership
N c= rate of partner exchange (years21)
N Xh(t)=number of susceptible hosts of host type h at time t
N Yhv (t)=number of type h hosts infected with virus type v at
time t
N N(t)= total number of hosts in the population at time t
N lv(t)= force of infection from hosts infected with virus type v at
time t (years21)
Model equations
The model is described mathematically using ordinary differen-
tial equations (1–6), where the force of infection is defined as
l0(t)~
bc
N(t)
Y 10 (t)zY
0
0 (t)
 
for the wild-type virus and
l1(t)~
bc
N(t)
Y 11 (t)zY
0
1 (t)
 
for the escape mutant virus. The total
population size is defined as N(t)~
P
h~1,2
Xh(t)z
P
v~1,2
Yhv (t)
 !
.
Susceptible, HLA mismatched
dX 0(t)
dt
~(1{p)B{ l0(t)zl1(t)zmð ÞX 0(t) ð1Þ
Susceptible, HLA matched
dX 1(t)
dt
~Bp{ l0(t)zl1(t)zmð ÞX 1(t) ð2Þ
Infected, WT, HLA mismatched
dY 00 (t)
dt
~l0(t)X
0(t)zyY 01 (t){(mza)Y
0
0 (t) ð3Þ
Infected, EM, HLA mismatched
dY 01 (t)
dt
~l1(t)X
0(t){yY 01 (t){(mza)Y
0
1 (t) ð4Þ
Infected, WT, HLA matched
dY 10 (t)
dt
~l0(t)X
1(t){wY 10 (t){(mza)Y
1
0 (t) ð5Þ
Infected, EM, HLA matched
dY 11 (t)
dt
~l1(t)X
1(t)zwY 10 (t){(mza)Y
1
1 (t) ð6Þ
Statistics
Minitab 14 was used to compare the observed and predicted
escape rates (Figure 3A). Firstly, we tested whether they are
correlated using a 2-tailed Pearson Correlation test. For this test, a
small p-value (i.e. p-value,0.005) indicates a strong correlation.
Since variables that are correlated are not necessarily equal in
magnitude, we also evaluated whether the observed and predicted
escape rates are approximately equal in magnitude. We present
the t-value relating to a 2-tailed paired t-test with a null hypothesis
that the difference in magnitude between the rates is equal to zero.
For this test, a t-value with a small magnitude (i.e. less than 1)
indicates that the variables are close in magnitude. Variables are
typically regarded as statistically different in magnitude if the
magnitude of the t-value is greater than 1.96. To meet the
normality conditions for the two tests described, both sets of escape
rates were first transformed according to f (x)~{ ln xz0:01ð Þ.
The observed and predicted changes in the escape prevalences
(Figure 3C) were compared using the same tests, but each were
first transformed according tof (x)~sgn(x)
ﬃﬃﬃﬃﬃ
DxD
p
. The observed
and predicted reversion rates (Figure 3B) could not be normalised,
therefore the correlation between these two variables was tested
using the non-parametric Kendall Tau test. However, transfor-
mation of each set of reversion rates according to
f (x)~{ ln xz0:01ð Þ was sufficient to meet the normality
conditions for the paired t-test.
Supporting Information
Table S1 A summary of mutations in HIV-1 gag, RT and nef
which have been reported in the literature as conferring CTL
escape and confirmed by in vitro tests.
Found at: doi:10.1371/journal.ppat.1001196.s001 (0.02 MB PDF)
Table S2 A summary of escape and reversion data from the
cross-sectional study (dataset 2) and the longitudinal cohort study
(dataset 4).
Found at: doi:10.1371/journal.ppat.1001196.s002 (0.03 MB PDF)
Table S3 A summary of published escape data from case reports
(dataset 3).
Found at: doi:10.1371/journal.ppat.1001196.s003 (0.03 MB PDF)
Table S4 A summary of published reversion data from case
reports (dataset 3).
Found at: doi:10.1371/journal.ppat.1001196.s004 (0.01 MB PDF)
Text S1 Analytic expressions representing the escape prevalence
under different circumstances.
Found at: doi:10.1371/journal.ppat.1001196.s005 (0.03 MB PDF)
Text S2 Supporting references.
Found at: doi:10.1371/journal.ppat.1001196.s006 (0.01 MB PDF)
Text S3 A detailed analysis describing how additional factors
could affect the evolution of escape mutants and thus affect our
inferred rates of escape and reversion rates from the cross-sectional
data (dataset 2).
Found at: doi:10.1371/journal.ppat.1001196.s007 (0.41 MB PDF)
Figure S1 Confidence intervals for escape and reversion rates
inferred from the cross-sectional data (dataset 2).
Found at: doi:10.1371/journal.ppat.1001196.s008 (0.04 MB PDF)
Figure S2 Sensitivity analysis showing how the assumed model
parameters affect our inferences from the cross-sectional data (c.f.
Figure 3).
Found at: doi:10.1371/journal.ppat.1001196.s009 (0.19 MB PDF)
Figure S3 Observed changes in the population escape preva-
lence over approximately 20 years (dataset 1).
Found at: doi:10.1371/journal.ppat.1001196.s010 (0.04 MB PDF)
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